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Abstract: Nonadherence to prescribed treatment is an important cause of difficult asthma. 
Rates of nonadherence amongst asthmatic patients have been shown to range between 30% 
and 70%. This is associated with poor health care outcomes and increased health care costs. 
There is no such thing as a “typical” nonadherent patient. The reasons driving nonadherence 
are multifactorial. Furthermore, adherence is a variable behavior and not a trait characteristic. 
Adherence rates can vary between the same individual across treatments for different conditions. 
There is no consistent link between socioeconomic status and nonadherence, and although 
some studies have shown that nonadherence is more common amongst females, this is not a 
universal finding. The commonly held perception that better adherence is driven by greater 
disease severity has been demonstrated to not be the case, in both pediatric and adult patients. 
Identification of nonadherence is the first step. If adherence is not checked, it is likely that poor 
adherence will be labeled as refractory disease. Failure to identify poor adherence may lead to 
inappropriate escalation of therapy, including the potential introduction of complex biological 
therapies. Surrogate measures, such as prescription counting, are not infallible. Nonadherence 
can be difficult to identify in clinical practice, and a systematic approach using a variety of tools 
is required. Nonadherence can be successfully addressed. Therefore, assessment of adherence is 
of paramount importance in difficult asthma management, in order to reduce exacerbations and 
steroid-related side effects as well as hospital and intensive care admissions, health care cost, 
and inappropriate treatment escalation. In this paper, we present an overview of the literature 
surrounding nonadherence in difficult asthma. We explore the facts and myths surrounding the 
factors driving nonadherence as well as how it can be identified and addressed.
Keywords: concordance, compliance, inhaled corticosteroids, drug monitoring
Introduction and objectives
Asthma is estimated to affect 300 million people worldwide and is a major preventable 
cause of morbidity and mortality.1,2 Approximately 5%–10% of asthmatic patients suffer 
from “difficult asthma,” which can be defined as persistent symptoms and/or frequent 
exacerbations despite prescription for maximal recommended inhaled corticosteroid 
(ICS) treatment in addition to other maintenance therapies3 (ie, prescribed treatment 
at Global Initiative For Asthma Step 4/5).4 One of the causes of difficult asthma is 
suboptimal adherence to prescribed medication, principally ICS treatment.
In this paper, we present an overview of the literature on nonadherence in difficult 
asthma. Our objectives are to review the problem of nonadherence in terms of its 
prevalence and demographic associations, methods of identification and lastly, the ways 
in which it can be addressed in clinical practice. We will examine the facts and myths 
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surrounding the condition and underline the importance of 
timely identification.
Definitions
The World Health Organization (WHO) defines adherence 
as “the extent to which a person’s behavior [...] corresponds 
with agreed recommendations from a health care provider.”5 
“Adherence,” as a term, has largely superseded “compliance,” 
which was felt to have a paternalistic connotation, ie, an 
implied patient subservience in the medication-prescription 
process. “Adherence” acknowledges the patient’s right to 
choose whether or not to follow these recommendations. 
Another term that is often used is “concordance,” which is 
a more complex idea incorporating the relationship between 
doctor and patient, and the extent to which both parties agree 
on the recommendations; it implies shared decision making 
in the management of the patient’s condition.6
Nonadherence is prevalent in all chronic diseases, and, in 
1979, a review of over 500 studies identified adherence to be 
approximately 50% in different conditions where long-term 
medication was prescribed, with a range of 0% to 100%.7
Nonadherence to inhaled 
corticosteroid therapy in asthma
Rates of nonadherence amongst asthmatic patients (to all 
medications, including theophylline as measured by serum 
levels) were shown to range between 30% and 70% in a 
1997 review;8 this is apparent irrespective of how adherence 
is measured, be it the percentage of prescribed medication 
taken, serum theophylline levels, days of medication 
adherence, or percentages of patients who are identified to 
be nonadherent to medication.8
The problem of suboptimal adherence is particularly 
obvious for ICS even with short-term use. For example, in 
a small study involving 20 asthmatic participants, after a 
5-week study employing electronic monitoring of inhaler use, 
only 40% of patients were found to be adherent.9 Another 
study, which looked at the effect of direct clinician-to-patient 
feedback on ICS use, found an overall baseline adherence to 
ICS of approximately 56%.10
Nonadherence to ICS is also associated with a poor 
health care outcome.11 A large study looking at 12,636 
patients attending the emergency department with an asthma 
exacerbation revealed that on the basis of pharmacy records, 
25.1% of patients had had ICS dispensed during the 12 months 
prior compared with 53.5% who had had a short-acting beta-2 
agonist (SABA) dispensed.12 This would indicate an apparent 
preference of reliever medication over maintenance in this 
group of asthmatics who had had a severe exacerbation. Two 
large Canadian case-control studies have looked at the effects 
of regular ICS use on hospitalization for asthma13 and on 
mortality,14 using prescription filling as a surrogate measure 
of medication use. Both studies drew data from a large health 
database with precise prescription data. They identified 30,569 
asthmatics aged between 5 and 44 years who had received three 
or more antiasthmatic medication prescriptions in a 1-year 
period between 1975 and 1991, and who had been followed 
up for at least 1 year. They looked at ICS prescriptions that 
were dispensed in the year prior to an admission to hospital. 
Regular use was defined as at least one ICS inhaler being 
dispensed per quarter (ie, 3-month period). Irregular use was 
defined as any other pattern. They found the overall rate of 
admission to hospital on account of asthma was 42.4 per 1000 
asthmatic patients per year (with the rate of first asthma-related 
hospitalization of 17.2 per 1000 patients per year). Regular use 
of ICS, as described above, was found to lead to an overall 
reduction in rate of hospital admission of 34%.13
For the mortality study,14 the same standard of regular 
ICS use was employed. There were 562 deaths in total in 
the 30,569-strong cohort. Seventy-seven of the deaths were 
felt to be due to asthma, and there were full data on 66 of 
these; these cases were matched with control patients from 
the database with similar duration and severity of disease 
who did not die. The mean number of ICS inhalers picked 
up in the 12 months prior to death was 1.18, compared with 
1.57 inhalers for the control group (93% of the inhalers were 
low-dose beclomethasone). Using a continuous dose-response 
analysis, the authors calculated a reduction of 21% in the rate 
of death from asthma with every additional ICS canister used 
in the preceding 12 months. They concluded from these data 
that regular use of low-dose ICS is associated with a reduction 
in asthma-related mortality at population level.14
The “typical” nonadherent patient
There is a perception that the “typical” nonadherent patient 
can be easily identified in the clinic – eg, the patient who 
engages in high-risk behaviors such as smoking, who has a 
chaotic lifestyle, or who has some other obvious identifiable 
reason for poor adherence to medication. However, whilst 
these issues may be relevant in some cases, there is no such 
thing as a “typical” nonadherent patient, and one has to 
consider many factors. It is useful to think of nonadherence 
as falling into two broad categories – nonintentional and 
intentional – although these should not be thought of as 
mutually exclusive.15 Nonintentional nonadherence occurs 
when the patient wants to take the medication but is unable 
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to as a result of practical barriers – eg, the patient simply 
forgets to take it, misunderstands or forgets the instructions 
given by the caregiver, cannot take it (due to poor inhaler 
technique), can’t afford the medication, etc. Intentional 
nonadherence occurs when the patient decides not to follow 
treatment recommendations. The reasons for this pattern of 
behavior are more complex and include denial, medication 
and disease beliefs, and secondary gain. Barriers, therefore, in 
the nonintentional and intentional paradigms of nonadherence 
are practical and perceptual, respectively. Practical barriers 
can largely be solved by practical solutions. With perceptual 
barriers, however, a different approach is required.
Demographic associations  
with poor adherence
There is no consistent link between socioeconomic status 
and nonadherence.15 A meta-analysis looking at factors 
associated with adherence did reveal, however, that there 
was a positive correlation between level of adherence and 
measures of income, but not with socioeconomic status 
generally.16 Some studies have reported that nonadherence 
is more common amongst females. A Brazilian study 
looking at 131 moderate-to-severe asthmatics given 
free-of-charge ICS/long-acting beta-2 agonist (LABA) 
combination inhalers for 3 months found that (on the 
basis of the amount used from each inhaler) being male 
was protective against nonadherence (where adherence 
was defined as using more than 85% of the medication); 
however, this association was not seen in a multivariate 
analysis that took into account the other dependent 
variables, such as race, marital status, smoking status, 
and asthma severity. Interestingly, in this model, the only 
consistent association was a higher rate of adherence 
amongst patients with a greater severity of asthma.17
Another study carried out in Detroit, MI, USA 
examined adherence differences between white patients 
and African-American patients, and examined data from 
prescription filling and medical records.18 Amongst white 
patients, female adherence was significantly lower than 
in men. They also identified poorer adherence in African-
American patients compared with white patients. African-
American patients also had a lower median household income 
and a higher index crime rate in their area of residence and 
were more likely to live in an inner-city location. Amongst 
African-American patients, ICS adherence was found to be 
negatively correlated with local crime rate.18 In a related study 
by the same authors of a different cohort (where adherence was 
classified as 80% prescription filling), they again identified 
female sex along with younger age and African-American 
race to be associated with nonadherence.19
However the association with female sex is not a universal 
finding. A postal survey carried out in Portland, OR, USA 
amongst a sample of adults with persistent asthma, which was 
specifically designed to assess sex differences in various aspects 
of the condition, found that women were more likely to regularly 
monitor their condition via peak flow, to attend a regular 
clinician for their asthma, and to have a written management 
plan.20 A Swedish study used prescription refilling to assess 
adherence to ICS, including combination (ICS with LABA) 
inhalers as well as anticholinergic inhalers, in patients aged 
60 years or over with asthma or chronic obstructive pulmonary 
disease (COPD) (the analysis was done for both diseases 
together).21 This study also failed to notice any sex association 
with poor adherence. For ICS, it was noted that 59% of patients 
were “underadherent” (ie, less than 80% of prescriptions filled), 
while another 12% were found to be “overadherent” (more than 
120% of prescriptions filled), with more oversupply noted with 
combination inhalers.21
A follow-up study to both the European Community 
Respiratory Health Survey I and II, which assessed how 
patients’ self-reported adherence to asthma treatment had 
changed since their involvement in the previous surveys, 
revealed no significant differences between the sexes in terms 
of either increased adherence or persistence of adherence.22 
This global study did note that while adherence remained low 
worldwide, it did increase in continental and extra-European 
areas. The study also noted that the best predictors of 
increased or persistent adherence were regular appointments 
with a specialist and positive beliefs about the medication.
Mood disorder may affect adherence with medication. 
A positive association has been demonstrated between 
depressive symptoms and poor adherence (less than 50%) to ICS 
and oral corticosteroid treatment in the 2 weeks after discharge 
from hospital following an asthma-related admission.23
It is also important to note that adherence rates can vary 
within the same individual across treatments for different 
conditions. A study carried out via online surveys in the 
USA looked at cost-related medication underuse for chronic 
illnesses.24 This study demonstrated that large numbers of 
adults with chronic illnesses had taken less medication than 
prescribed, specifically because of the cost. Furthermore, 
participants were noted not to be cutting back uniformly 
on treatments for different conditions.24 Thus, there is no 
“typical” nonadherent patient. Adherence is a variable 
behavior and not a trait characteristic, and in fact, most people 
will be nonadherent some of the time.15
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Adherence in clinical trials
In a 2-year-long Norwegian pediatric study, it was noted that 
there was relatively high adherence at the beginning of the 
trial period, but that this fell over subsequent months.25 This 
study calculated adherence on the basis of doses used from 
inhaler devices that were returned; participants were 7- to 
16-year-old mild asthmatics and were not told that their 
adherence was being monitored. This implies that adherence 
will fall even in the well-monitored clinical trial scenario, 
making it essential that adherence is always measured in 
such studies. This study noted that the 7- to 9-year-old group 
was consistently more adherent than the 10- to 16-year-old 
group, and significantly so for the first 3 months, which 
may reflect greater parental influence in younger children. 
Also, they noted that during the last 6 months of the study, 
patients on placebo had significantly lower adherence than 
those receiving ICS, which may reflect the identification of 
a therapeutic benefit of the ICS.25
In a large adult study – the Gaining Optimal Asthma 
Control Study – ICS and inhaled ICS/LABA combination 
therapy (ICT) were compared, using a dose escalation 
strategy, to improve asthma control.26 Despite monitoring 
in the trial, 11% of patients used less than 80% of their 
medication, based on the dose counter on the inhaler 
device.
Nonadherence and disease severity
A commonly held perception is that more severe disease, 
more disease-related morbidity will drive better adherence, 
and this is particularly the case with a medication like ICS in 
asthma, which has good clinical efficacy. However, a study at 
a regional tertiary referral difficult asthma service in Northern 
Ireland revealed that 35% of new referrals were filling 50% or 
less of prescriptions for ICT.27 Consistent with other studies 
in severe and difficult-to-control asthma, the majority (62% 
of the 182 consecutive referrals) were female, and female 
patients were significantly more likely to be nonadherent to 
ICT – 42% female versus 23% male. Importantly, in this 
study, the prescription filling as a surrogate of poor adherence 
was validated using a patient concordance interview. Patients 
filling 50% or less of their ICT prescriptions were also more 
likely to have had three or more hospital admissions in the 
preceding 12 months. Furthermore, they were more likely to 
be using home nebulizers, and to use a significantly greater 
amount of nebulized short-acting beta-2 agonist (SABA) 
medication.27
Similar results were found at another specialist UK 
difficult asthma service in Leicester.28 Using prescription 
records, suboptimal adherence to ICS and ICT (defined 
as ,80% prescriptions filled) was found in 75 of 115 patients 
(65.2%) – of note, in the Belfast study, ,80% prescription 
filling was found in 64% of patients.29 Again, poorer asthma 
control and increased health care utilization was noted. 
Patients with poor adherence to ICS were found to have 
a significantly lower postbronchodilator 1-second forced 
expiratory volume (FEV
1
) (percentage predicted mean 75.5% 
vs 84.3%) and higher sputum eosinophil count (mean 4.6% 
vs 2.3%) than those with adequate ICS adherence.28 Also, 
patients with poor prescription filling were more likely to 
have been admitted to an intensive care unit for ventilation 
on account of their asthma (19.2% vs 2.6%).30
The finding of poor adherence associated with difficult-to-
control asthma is also seen in children. In a pediatric study of 
referrals to a tertiary referral centre in London, 71 children 
who had persistent symptoms and frequent exacerbations 
despite treatment of at least step 4 had a nurse-led home visit 
as part of a multidisciplinary assessment.31 Adherence was 
addressed as part of this visit, which included an examination 
of the patient’s medication usage and inhaler technique. Only 
43% of patients had filled more than 80% of prescriptions for 
their asthma medication issued, and 30% of patients had filled 
less than 50% asthma prescriptions issued. Poor symptom 
control found in 48% of the children under study was felt to 
be contributed to by poor adherence, unsuitable device, and 
poor inhaler technique.31
Identifying nonadherence in asthma
Surrogate measures of adherence, such as prescription 
counting and inhaler weighing/dose counting, are not 
infallible. Patients may pick up their inhalers, but not use 
them. Also, prescription records give a percentage of the 
amount of inhalers that should have been used over a certain 
time period – ie, 6–12 months. This gives information about 
long-term use but does not acknowledge short-term changes 
in adherence behavior. Inhaler weighing and dose counting 
can be confounded by “test doses” or “dumping,” in which the 
medication is simply discharged several times by the patient to 
bring ostensible usage up to a more “satisfactory” level.32
More objective measures for monitoring inhaled 
medication are available, such as electronic monitoring, but 
these are expensive for routine clinical use and prone to the 
Hawthorne effect, whereby patients improve their adherence 
transiently when they know that it is being monitored.
Physician assessment, patient diaries, and self-reporting 
have been shown to give an overestimation of compliance 
when compared with objective electronic measures.11,33–35 
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The accuracy of self-reporting is likely to be dependent on the 
reason for nonadherence and the setting of the study – eg, an 
anonymous questionnaire is more likely to be precise and less 
open to overestimation than a one-to-one interview at clinic.
In the Northern Ireland study, 45 of 51 (88%) patients 
who were found to be filling 50% or fewer ICT prescriptions 
admitted variability in taking their combination treatment, 
in accordance with the degree of nonadherence identified 
on prescription records at a subsequent clinical interview.27 
Of the six patients who continued to deny nonadherence 
at the interview, three were found to be nonadherent to 
prednisolone or theophylline, based on serum assays (despite 
also reporting to be taking these medications). However, all 
patients had denied nonadherence prior to the concordance 
interview with the prescription records, and it was felt that in 
the absence of the prescription data, a concordance interview 
would not have been feasible, as the patients would not have 
felt able to admit and discuss their nonadherence.
A similar picture emerged with oral prednisolone, 
where 86% of the patients interviewed who had been 
found to be nonadherent to oral prednisolone, based on 
serum prednisolone/cortisol measurements, admitted poor 
adherence.27 This study emphasized the importance and 
utility of objective markers of nonadherence to facilitate a 
concordance discussion.
Similar findings were obtained in a study carried out at 
the Royal Brompton Hospital difficult asthma clinic.36 Of 
100 newly referred patients who were evaluated, 28 patients 
were receiving 15 mg or more of maintenance prednisolone. 
Of these, nine (32.1%) were found to be nonadherent on the 
basis of prednisolone/cortisol blood assays.
We have recently demonstrated that the degree of 
suppression in fractional exhaled nitric oxide (FeNO) 
occurring with directly observed inhaled steroid therapy can 
be used to identify nonadherence to ICS in a difficult asthma 
population.37 This test could be used prior to the introduction 
to complex biological therapies targeting eosinophilic disease 
(eg, mepolizumab), to ensure the clinical problem is not due to 
nonadherence with inhaled steroids. We are currently examining 
delivery of this test using remote monitoring technologies, and 
in the specialized difficult asthma setting, this test may have 
an important role in distinguishing the truly refractory patient 
requiring treatment escalation from the nonadherent patient.
Do oral treatments or once-a-day 
inhaler regimes improve adherence?
A large multicenter study, in which 1037 mild-to-moderate 
asthmatics were analyzed, looked at once-daily versus 
twice-daily dosing of ICS treatment.38 Adherence was 
measured by dose counter on the inhaler and by patient 
self- reporting. The trial was of a short duration (12 weeks), 
and visits were on a monthly basis. Patients were not told 
that adherence was being observed. Adherence was found to 
be significantly higher (using the dose counter) in the once-
daily dosing group (once-daily adherence, 93.3%; twice daily, 
89.5%). There were no differences in health care outcomes 
between the two groups. The adherence rates in both groups 
were very high, and this may be due to the short duration 
of the study coupled with the Hawthorne effect. A study of 
longer duration would be beneficial in order to investigate 
this further.
A year-long study looked at adherence in economically 
disadvantaged African-American young people.39 Researchers 
used electronic monitoring to look at the adherence to 
inhaled fluticasone and oral montelukast in 346 participants. 
Adherence to montelukast was higher than to fluticasone, 
but over the course of the 12 months, adherence to both 
medications fell drastically (at the end of the year, participants 
were taking 23% of prescribed doses of ICS and 31% of 
montelukast). They noted no relationship between adherence 
and clinical outcome in the overall population. In subjects with 
“worse asthma,” as defined by decreased lung function and 
increased use of rescue medication, there was better clinical 
response with better inhaled steroid adherence. In addition, 
during an open-label extension to the study, with a simplified 
regime, adherence was worse with both medications.39
When identified, is nonadherence 
easy to address in clinical practice?
A Cochrane review looked at interventions for enhancing 
adherence to medication.40 They looked at 13 asthma 
intervention studies in different clinical settings, eg, 
postadmission and primary/secondary care, with the 
“intervention” usually being a management plan. These 
studies involved mixed populations, eg, asthma and COPD, 
asthma, and rhinitis. Six of these reported adherence 
improvement using different measures, eg, patient self-report 
and/or physician estimate. Only two studies used prescription 
records. Three studies showed changes in a health care 
outcome, eg, improved peak flow or use of reliever. They 
concluded that the data was “surprisingly weak” and that 
“increasing effectiveness of adherence interventions” would 
have a “greater impact than improvement in specific medical 
treatments.”40
We have shown in a recent study that 31 of 83 patients 
(37%) identified as nonadherent using prescription records 
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(#50% filling) became adherent following a concordance 
interview,41 which involved conveying the fact to patients 
that they were nonadherent and agreeing on a treatment 
plan to improve adherence. This newly adherent group was 
predominantly female (68%), and 39% had been tertiary 
referrals. Twenty-seven patients (90%) remained adherent 
at 12 to 18 months following the concordance discussion. 
Improved adherence was again associated with improved 
outcomes – prescribed daily dose of ICS and number of 
rescue courses of prednisolone were significantly reduced. 
FEV
1
 was significantly improved and there were significantly 
less hospital admissions on account of asthma. We also 
carried out a small randomized controlled trial (n = 18) of 
1-year duration in which nonadherent patients were randomly 
allocated to receive either a specially designed menu-driven 
behavioral intervention in addition to the usual care from 
the difficult asthma service, or the usual care only.41 The 
primary outcome of “% combination ICT inhalers filled” was 
significantly improved (37.6% to 61.9% in the intervention 
group vs 31.7% to 28.8% in the control group). The number 
needed to treat was found to be three.
The implications of nonadherence 
in difficult asthma
Nonadherence in asthma, particularly those with more difficult-
to-control asthma, is associated with poor asthma outcome.27,28,31 
It also leads to increased health care cost.8,42–44
Nonadherence in difficult asthma can also lead to 
problems in identifying and understanding refractory 
asthma. All definitions of refractory or severe asthma are 
based on both a failure to respond to high dose asthma 
therapy and the assumption that the patient is taking this 
therapy adequately. If adherence is not checked, then it 
is likely that poor adherence will be labeled as refractory 
disease. Furthermore, failure to identify poor adherence will 
also lead to inappropriate escalation of therapy, including 
the potential introduction of complex biological therapies. 
The current National Institute for Clinical Excellence 
guidance on the use of omalizumab indicate that it should 
be used as an “add-on to optimised standard therapy,” which 
is defined as
a full trial of, [...] and documented compliance with 
inhaled high-dose corticosteroids, long-acting beta-2 
agonists, leukotriene receptor antagonists, theophyllines, 
oral corticosteroids, and smoking cessation if clinically 
appropriate.45
It does not indicate how this “compliance” should be 
checked. The guidance recommends that treatment with 
omalizumab be considered in
people aged 6 years and older who need continuous or 
frequent treatment with oral corticosteroids (defined as 4 
or more courses in the previous year).45
The problem remains that it may be simple nonadherence 
to combination inhaled therapy that leads to patients being 
prescribed maintenance or rescue treatment with oral 
corticosteroids and that expensive monoclonal antibody 
therapies may not be necessary to achieve disease control. 
This is a situation in which the target population identified 
by the National Institute for Clinical Excellence does not 
always align with clinical appropriateness if nonadherence 
is driving the “continuous or frequent treatment with oral 
corticosteroids.”45
Nonadherence also poses problems with phenotype-
specif ic prescribing in refractory asthma. The novel 
anti-Interleukin (IL)-5 monoclonal antibody treatment 
mepolizumab has been shown to reduce the frequency 
of exacerbations in refractory eosinophilic asthma.46,47 
However, nonadherence has been shown to be associated 
with significantly higher sputum eosinophils.28 Therefore, 
once again it may be that it is simply a question of identifying 
and addressing nonadherence rather than escalating to an 
expensive complex therapy. We believe tests such as the 
FeNO-suppression test, allied with other direct and surrogate 
measures of nonadherence should be examined prior to 
commencing complex biologic therapies.
Conclusion
Nonadherence is very common across all severities of 
asthma and is a common reason for “difficult asthma” 
in adults and children. It is difficult to identify in routine 
clinical practice, requiring a systematic approach 
using a variety of tools. Biomarkers of adherence or of 
steroid exposure should be used to prevent inappropriate 
escalation to complex therapies in difficult asthma. When 
nonadherence is identified, it can be successfully targeted. 
Furthermore, it is important to remember that the definitions 
of severe asthma and the guidelines for phenotype-specific 
management are all predicated on the assumption of 
treatment adherence.
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